Clinical Trial Update: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study update for brexucabtagene autoleucel (KTE-X19) in adult Japanese patients with relapsed/refractory mantle cell lymphoma or relapsed/refractory B-p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-precursor Acute Lymphoblastic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• KTE-X19 (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING